[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"paraplegia-and-tetraplegia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:paraplegia-and-tetraplegia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,83,103,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100638318","phase-2-pilot-study-of-galantamine-to-treat-metabolic-syndrome-in-people-with-chronic-traumatic-spinal-cord-injury-sci-100638318",false,"NCT07625332","Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)","Pilot Study of Tolerability and Preliminary Efficacy of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)","Inclusion Criteria:\n\n* Adults aged 21-75 years (male or female)\n* Chronic (≥1 year post injury) traumatic non-progressive spinal cord injury (SCI)\n* Wheelchair user for community mobility\n* Injury level of tetraplegia (cervical level) or paraplegia (all levels)\n* SCI-specific obesity indicated by waist circumference ≥94 cm\n* Resting heart rate \\>45 bpm based on 10 measurements over 10 minutes\n* Without clinically significant cardiovascular abnormalities as indicated by 12-lead ECG\n* Tolerable bowel routine indicated by a score of \\\u003C10 on the International SCI Bowel Function Data Set (ISCI-BDS)\n* Metabolic Syndrome (MetS) defined by the presence of at least three of the following: (1) obesity indicated by SCI-specific waist circumference ≥94 cm, (2) elevated fasting glucose ≥100 mg\u002FdL, (3) dyslipidemia: high triglycerides ≥150 mg\u002FdL or low HDL cholesterol \\\u003C40 mg\u002FdL for men and \\\u003C50 mg\u002FdL for women, (4) C-reactive protein (CRP) levels \\>1 mg\u002FdL\n* Able to understand and communicate in English at the level of describing adverse event frequency and severity and completing validated outcome measures\n* Willingness to comply with all study procedures and availability for the duration of the study\n* Provision of signed and dated informed consent form\n\nExclusion Criteria:\n\n* Diagnosis of neurological injury or condition other than SCI\n* Progressive condition that would be expected to change neurological status\n* Signs and symptoms of cardiovascular disease or cardiac arrhythmias\n* Resting heart rate \\\u003C45 bpm\n* Score of 10 or greater on the ISCI-BDS v2.1 indicating moderate to severe neurogenic bowel dysfunction\n* Severe concurrent medical disease, condition, or illness judged to be contraindicated by the site physician\n* Psychopathology documented in the medical record or history that may conflict with study objectives\n* Pregnancy (participant reported or determined by clinical lab test), women who plan to become pregnant, or women who are nursing during the study\n* Active cancer or currently in treatment for cancer\n* Triglyceride levels ≥400 mg\u002FdL\n* Chronic use of medications with known or probable interactions with galantamine\n* Enrolled in another research study that is likely to interfere with conduct or results of the current study\n* Any other reason the site physician feels that participation is contraindicated","ALL","21 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. Here, the drug is considered experimental for the purposes of this study.",[28,29,30,31],"Spinal Cord Injury","Traumatic Spinal Cord Injury","Paraplegia and Tetraplegia","Metabolic Syndrome",[33,34,35,36],"spinal cord injury","tetraplegia","paraplegia","metabolic syndrome","RECRUITING","2026-05-28",{"date":40,"type":41},"2026-06-04","ACTUAL",{"date":43,"type":21},"2026-06-15",{"date":45,"type":21},"2027-12",{"name":47,"class":48},"Northwell Health","OTHER",3,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100634184","self-balancing-personal-exoskeleton-for-sci-wip-100634184","NCT07536386","Self-balancing Personal Exoskeleton for SCI (WIP)","Empowering Mobility in People With Spinal Cord Injury With a Hands-free, Self-balancing Personal Exoskeleton","User inclusion criteria:\n\n* Any gender, age 18 years or older\n* Motor complete or incomplete SCI at any level\n* ≥ 6 months post SCI\n* Able and willing to attend 9 visits to the center, including sessions of training and assessments of one-to-three hours duration\n* Able to read, understand, and provide informed consent.\n* Patients affiliated to a social security system.\n\nUser exclusion criteria:\n\n* Diagnosis of neurological injury other than SCI;\n* Progressive condition that would be expected to result in changing neurological status;\n* Severe concurrent medical disease, illness or condition judged to be contraindicated by the site physician;\n* Unhealed or unstable traumatic or high impact lower extremity fracture of any duration that is, in the clinical judgement of the study physician, exclusionary for standing and walking;\n* Individual with history of osteoporotic fracture and \u002F or pathology or treatment causing secondary osteoporosis.\n* Untreatable severe spasticity judged to be contraindicated by the site physician;\n* Untreated\u002Funcontrolled hypertension, as judged to be contraindicated by the site physician;\n* Unresolved orthostatic hypotension (change from baseline seated BP to a fall in 20mmHg SBP and\u002For fall in 10mmHG DBP and symptoms when standing), or as judged to be contraindicated by the site physician;\n* Open or unhealed skin pressure sores, abrasions, or bruises at any of the contact points of the exoskeleton;\n* Morphological contraindications to the use of the device;\n* Uncorrectable leg length discrepancy over 2 cm (about 0.79 in) when using additional correction tools;\n* Unable to effectively operate the device with a controller, due to functional and\u002For cognitive impairment, evaluated based on the ability to manipulate the joystick in all direction, press and identify buttons on the controller.\n* Improper fitting in the device;\n* Psychopathology documentation in the medical record that may conflict with study objectives;\n* Pregnancy or women who plan to become pregnant during the study period;\n* Concurrent participation in another interventional trial;\n* Uncontrolled autonomic dysreflexia;\n* Ventilator use at the time of the exoskeleton use.\n* Patient under legal protection.\n\nCompanion inclusion criteria\n\n* Any gender, age 18 years or older.\n* Willingness to attend 9 to 10 visits to the center, including sessions of training and assessments of one-to-three hours duration with the SCI user.\n* Able to read, understand and provide informed consent.\n\nCompanion exclusion criteria:\n\n* Inability to communicate due to cognitive and language disorders;\n* Any disease, concomitant injury, or condition that interferes with the performance or interpretation of the protocol- specified assessments;\n* Insufficient strength and performance capability, evidenced by the ability to hold and retain the device in case of unbalance\u002Ffall;\n* Insufficient availability to complete the study;\n* Concurrent participation in another interventional trial.","18 Years",{"count":59,"type":21},10,[61],"NA","This study aims to demonstrate the safety and effectiveness of the personal exoskeleton in individuals with spinal cord injury (SCI).",[64,30],"Spinal Cord Injuries",[28,66,67,68,69,70,71],"Robotics","Community use","Hands-free exoskeleton","Overground exoskeleton","Walking","Self-balancing","2026-04-10",{"date":74,"type":41},"2026-04-17",{"date":76,"type":41},"2026-02-10",{"date":78,"type":21},"2026-04-30",{"name":80,"class":81},"Wandercraft","INDUSTRY",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":55,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":62,"conditions":93,"keywords":94,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":82},"100610011","self-balancing-personal-exoskeleton-for-sci-winy-100610011","NCT07222033","Self-balancing Personal Exoskeleton for SCI (WINY)","SCI user inclusion Criteria:\n\n* Any gender, age 18 years or older;\n* Motor complete or incomplete SCI with lesions at or above T6;\n* ≥ 6 months post SCI;\n* Able and willing to attend 9 to 10 visits1 to the center, including sessions of training and assessments of one-to-three hours duration;\n* Able to read, understand, and provide informed consent;\n* Living in the US and speaks English.\n\nSCI user exclusion Criteria:\n\n* Diagnosis of neurological injury other than SCI;\n* Progressive condition that would be expected to result in changing neurological status;\n* Severe concurrent medical disease, illness or condition judged to be contraindicated by the site physician;\n* Unhealed or unstable traumatic or high impact lower extremity fracture of any duration that is, in the clinical judgement of the study physician, exclusionary for standing and walking;\n* Knee (proximal tibia and\u002For distal femur) BMD \\\u003C0.60 gm\u002Fcm2;\n* Total hip BMD T-scores \\\u003C -3.5;\n* Fragility, minimal trauma, or low impact fracture of the lower extremity since SCI;\n* Untreatable severe spasticity judged to be contraindicated by the site physician;\n* Untreated\u002Funcontrolled hypertension, as judged to be contraindicated by the site physician;\n* Unresolved orthostatic hypotension (change from baseline seated BP to a fall in 20mmHg SBP and\u002For fall in 10mmHG DBP and symptoms when standing), or as judged to be contraindicated by the site physician;\n* Open or unhealed skin pressure sores, abrasions, or bruises at any of the contact points of the exoskeleton;\n* Morphological contraindications to the use of the device;\n* Uncorrectable leg length discrepancy over 2 cm (about 0.79 in) when using additional correction tools;\n* Unable to effectively operate the device with a hand-control interface, due to functional and\u002For cognitive impairment, evaluated based on the ability to manipulate the joystick in all direction, press and identify buttons on the hand control interface.\n* Improper fitting in the device;\n* Psychopathology documentation in the medical record that may conflict with study objectives;\n* Pregnancy or women who plan to become pregnant during the study period;\n* Concurrent participation in another interventional trial;\n* History of uncontrolled autonomic dysreflexia;\n* Presence colostomy and\u002For urostomy;\n* Ventilator use at the time of the exoskeleton use;\n\nCompanion inclusion Criteria:\n\n* Any gender, age 18 years or older;\n* Willingness to attend 9 to 10 visits to the center, including sessions of training and assessments of one-to-three hours duration with the SCI user;\n* Able to read, understand and provide informed consent;\n* Living in the US and speaks English.\n\nCompanion exclusion Criteria:\n\n* Inability to communicate with an assistant due to cognitive and language disorders;\n* Any disease, concomitant injury, or condition that interferes with the performance or interpretation of the protocol- specified assessments;\n* Insufficient strength and performance capability, evidenced by the ability to hold and retain the device in case of unbalance\u002Ffall;\n* Insufficient availability to complete the study;\n* Concurrent participation in another interventional trial.",true,{"count":91,"type":21},12,[61],[28,30],[28,66,67,68,69,70,71],"2026-01-29",{"date":97,"type":41},"2026-02-02",{"date":99,"type":41},"2025-08-11",{"date":101,"type":21},"2026-05-31",{"name":80,"class":81},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":55,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":89,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":62,"conditions":112,"keywords":114,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":119,"locationsCount":82},"100578647","self-balancing-personal-exoskeleton-for-sci-site-2-100578647","NCT06814015","Self-balancing Personal Exoskeleton for SCI (Site 2)","SCI user inclusion Criteria:\n\n* Any gender, age 18 years or older;\n* Motor complete or incomplete SCI with lesions at or above T6;\n* ≥ 6 months post SCI;\n* Able and willing to attend 9 to 10 visits1 to the center, including sessions of training and assessments of one-to-three hours duration;\n* Able to read, understand, and provide informed consent;\n* Living in the US and speaks English.\n\nSCI user exclusion Criteria:\n\n* Diagnosis of neurological injury other than SCI;\n* Progressive condition that would be expected to result in changing neurological status;\n* Severe concurrent medical disease, illness or condition judged to be contraindicated by the site physician;\n* Unhealed or unstable traumatic or high impact lower extremity fracture of any duration that is, in the clinical judgement of the study physician, exclusionary for standing and walking;\n* Knee (proximal tibia and\u002For distal femur) BMD \\\u003C0.60 gm\u002Fcm2;\n* Total hip BMD T-scores \\\u003C -3.5;\n* Fragility, minimal trauma, or low impact fracture of the lower extremity since SCI;\n* Untreatable severe spasticity judged to be contraindicated by the site physician;\n* Untreated\u002Funcontrolled hypertension, as judged to be contraindicated by the site physician;\n* Unresolved orthostatic hypotension (change from baseline seated BP to a fall in 20mmHg SBP and\u002For fall in 10mmHG DBP and symptoms when standing), or as judged to be contraindicated by the site physician;\n* Open or unhealed skin pressure sores, abrasions, or bruises at any of the contact points of the exoskeleton;\n* Morphological contraindications to the use of the device;\n* Uncorrectable leg length discrepancy over 2 cm (about 0.79 in) when using additional correction tools;\n* Unable to effectively operate the device with a hand-control interface, due to functional and\u002For cognitive impairment, evaluated based on the ability to manipulate the joystick in all direction, press and identify buttons on the hand control interface.\n* Improper fitting in the device;\n* Psychopathology documentation in the medical record that may conflict with study objectives;\n* Pregnancy or women who plan to become pregnant during the study period;\n* Concurrent participation in another interventional trial;\n* History of uncontrolled autonomic dysreflexia;\n* Presence colostomy and\u002For urostomy;\n* Ventilator use at the time of the exoskeleton use;\n* Insufficient strength and performance capability (the ability to transfer into\u002Fout of the device or perform other training tasks with assistance).\n\nCompanion inclusion Criteria:\n\n* Any gender, age 18 years or older;\n* Willingness to attend 9 to 10 visits to the center, including sessions of training and assessments of one-to-three hours duration with the SCI user;\n* Able to read, understand and provide informed consent;\n* Living in the US and speaks English.\n\nCompanion exclusion Criteria:\n\n* Inability to communicate with an assistant due to cognitive and language disorders;\n* Any disease, concomitant injury, or condition that interferes with the performance or interpretation of the protocol- specified assessments;\n* Insufficient strength and performance capability, evidenced by the ability to hold and retain the device in case of unbalance\u002Ffall;\n* Insufficient availability to complete the study;\n* Concurrent participation in another interventional trial.",{"count":110,"type":21},24,[61],[113,30],"Spinal Cord Injuries (SCI)",[28,66,67,68,69,70,71],{"date":97,"type":41},{"date":117,"type":41},"2025-03-31",{"date":101,"type":21},{"name":80,"class":81},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":55,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":89,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":62,"conditions":128,"keywords":129,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":134,"locationsCount":82},"100575845","self-balancing-personal-exoskeleton-for-sci-100575845","NCT06777576","Self-balancing Personal Exoskeleton for SCI","SCI user inclusion Criteria:\n\n* Any gender, age 18 years or older;\n* Motor complete or incomplete SCI with lesions at or above T6;\n* ≥ 6 months post SCI;\n* Able and willing to attend 9 to 10 visits1 to the center, including sessions of training and assessments of one-to-three hours duration;\n* Able to read, understand, and provide informed consent;\n* Living in the US and speaks English.\n\nSCI user exclusion Criteria:\n\n* Diagnosis of neurological injury other than SCI;\n* Progressive condition that would be expected to result in changing neurological status;\n* Severe concurrent medical disease, illness or condition judged to be contraindicated by the site physician;\n* Unhealed or unstable traumatic or high impact lower extremity fracture of any duration that is, in the clinical judgement of the study physician, exclusionary for standing and walking;\n* Knee (proximal tibia and\u002For distal femur) BMD \\\u003C0.60 gm\u002Fcm2;\n* Total hip BMD T-scores \\\u003C -3.5;\n* Fragility, minimal trauma, or low impact fracture of the lower extremity since SCI;\n* Untreatable severe spasticity judged to be contraindicated by the site physician;\n* Untreated\u002Funcontrolled hypertension, as judged to be contraindicated by the site physician;\n* Unresolved orthostatic hypotension (change from baseline seated BP to a fall in 20mmHg SBP and\u002For fall in 10mmHG DBP and symptoms when standing), or as judged to be contraindicated by the site physician;\n* Open or unhealed skin pressure sores, abrasions, or bruises at any of the contact points of the exoskeleton;\n* Morphological contraindications to the use of the device;\n* Uncorrectable leg length discrepancy over 2 cm (about 0.79 in) when using additional correction tools;\n* Unable to effectively operate the device with a hand-control interface, due to functional and\u002For cognitive impairment, evaluated based on the ability to manipulate the joystick in all direction, press and identify buttons on the hand control interface.\n* Improper fitting in the device;\n* Psychopathology documentation in the medical record that may conflict with study objectives;\n* Pregnancy or women who plan to become pregnant during the study period;\n* Concurrent participation in another interventional trial;\n* History of uncontrolled autonomic dysreflexia;\n* Presence colostomy and\u002For urostomy;\n* Ventilator use at the time of the exoskeleton use.\n\nCompanion inclusion Criteria:\n\n* Any gender, age 18 years or older;\n* Willingness to attend 9 to 10 visits to the center, including sessions of training and assessments of one-to-three hours duration with the SCI user;\n* Able to read, understand and provide informed consent;\n* Living in the US and speaks English.\n\nCompanion exclusion Criteria:\n\n* Inability to communicate with an assistant due to cognitive and language disorders;\n* Any disease, concomitant injury, or condition that interferes with the performance or interpretation of the protocol- specified assessments;\n* Insufficient strength and performance capability, evidenced by the ability to hold and retain the device in case of unbalance\u002Ffall;\n* Insufficient availability to complete the study;\n* Concurrent participation in another interventional trial.",{"count":110,"type":21},[61],[113,30],[28,66,67,68,69,70,71],{"date":97,"type":41},{"date":132,"type":41},"2025-02-12",{"date":101,"type":21},{"name":80,"class":81}]